Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 5/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039012 | 0.83 | MAPK14 (0.48) | MAPTPOLBGSK3BMAPK14CLK1 | |
| SCHEMBL6772685 | 0.80 | MAPK14 (0.48) | GSK3BMAPK14CLK1DYRK1ADYRK1B | |
| SCHEMBL4709783 | 0.80 | VNN1 (0.52) | MAPTMAPK14MAPK1HTTP4HB | |
| SCHEMBL5226711 | 0.79 | MAPK14 (0.50) | MAPTGSK3BMAPK14GAACLK1 | |
| SCHEMBL29979531 | 0.78 | MAPT (1.00) | MAPTPOLBKDM4EGLANPC1 | |
| SCHEMBL26738 | 0.78 | MAPT (1.00) | MAPTPOLBKDM4EGLANPC1 | |
| SCHEMBL1757757 | 0.78 | MAPT (0.69) | MAPTPOLBKDM4EGLANPC1 | |
| SCHEMBL4852724 | 0.77 | MAPT (0.58) | MAPTPOLBKDM4EGLANPC1 | |
| SCHEMBL25223545 | 0.77 | MAPT (0.63) | MAPTPOLBKDM4EGLANPC1 | |
| SCHEMBL5034761 | 0.77 | CYP1A2 (0.45) | GSK3BMAPK14HTTL3MBTL1P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | disclosed |
| CN-1898217-A | Benzo'1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | NEURO3D (FR) | 2007-01-17 | — | — | CN | disclosed |
| EP-1697332-A1 | BENZO'1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063723-A1 | BENZO`1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2005-07-14 | — | — | WO | disclosed |
| EP-1548011-A1 | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof | NEURO3D (FR) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | PDE12, PDE2A, PDE3A | MAPT 2783/4885POLB 1178/4885GSK3B 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.